European Urology Oncology

Slides:

Advertisements

Similar presentations

Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer Victor E. Chen, BS, Erin.

Advertisements

Volume 28, Issue 12, Pages (December 2016)

Volume 165, Issue 5, Pages (May 2001)

Diabetic Cardiovascular Disease Predicts Chronic Kidney Disease Awareness in the Kidney Early Evaluation Program Cardiorenal Med 2011;1:45–52 - DOI: /

Oncol Res Treat 2016;39: DOI: /

The effect of perioperative chemotherapy for patients with an adenocarcinoma of the gastroesophageal junction: A propensity score matched analysis K.

Pulmonary Hypertension Is Associated with Mortality and Cardiovascular Events in Chronic Kidney Disease Patients Am J Nephrol 2017;45: DOI: /

European Urology Focus

European Urology Focus

Volume 66, Issue 6, Pages (December 2014)

Volume 63, Issue 5, Pages (May 2013)

Volume 199, Issue 4, Pages e235-e236 (April 2018)

European Urology Oncology

Control of Prostate Cancer by Transrectal HIFU in 227 Patients

European Urology Oncology

Ashish M. Kamat, Sima Porten European Urology

Volume 72, Issue 5, Pages (November 2017)

Volume 63, Issue 4, Pages (April 2013)

Volume 63, Issue 1, Pages (January 2013)

European Urology Oncology

European Urology Oncology

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 73, Issue 2, Pages (February 2018)

Volume 61, Issue 4, Pages (April 2012)

Volume 69, Issue 5, Pages (May 2016)

Volume 61, Issue 6, Pages (June 2012)

European Urology Oncology

Volume 64, Issue 3, Pages (September 2013)

European Urology Oncology

European Urology Oncology

Volume 148, Issue 1, Pages (January 2018)

Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients Timo F.W. Soeterik,

Volume 71, Issue 6, Pages (June 2017)

Stephen B. Williams, Ashish M

Volume 64, Issue 4, Pages (October 2013)

Volume 66, Issue 6, Pages (December 2014)

Volume 66, Issue 6, Pages (December 2014)

Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review Sven van.

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA Nawar Hanna, Quoc-Dien Trinh,

European Urology Oncology

Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy Matthew Mossanen, Kenneth.

European Urology Oncology

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

European Urology Oncology

European Urology Oncology

Gender differences in treatment outcomes of tuberculosis patients in Taiwan: a prospective observational study J.-Y. Feng, S.-F. Huang, W.-Y. Ting, Y.-C.

Development and Validation of an Improved Pathological Nodal Staging System for Urothelial Carcinoma of the Bladder Devin N. Patel, Michael Luu, Zachary.

Epidemiology of Renal Cell Carcinoma

Kaplan-Maier survival curves of 10-year DFS (A and B) and OS (C and D) according to PS 0 and PS≥1 in patients treated with adjuvant chemotherapy after.

Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature Liliana Vartolomei, Shahrokh F. Shariat, Mihai.

European Urology Oncology

The Cost to Medicare of Bladder Cancer Care

European Urology Oncology

European Urology Oncology

It’s All in the “Swerve of the Curve”

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

European Urology Oncology

Luis F. Tapias, MD, Douglas J. Mathisen, MD, Cameron D

Volume 54, Issue 1, Pages (July 2008)

European Urology Oncology

European Urology Oncology

European Urology Oncology

Maximilian Burger, Ashish M. Kamat, David McConkey

How to Treat a Patient with T1 High-grade Disease and No Tumour on Repeat Transurethral Resection of the Bladder? Shahrokh Shariat, Paolo Gontero, James.

Early Surgical Results After Pneumonectomy for Non-Small Cell Lung Cancer are not Affected by Preoperative Radiotherapy and Chemotherapy Tomas Gudbjartsson,

European Urology Oncology

Morgan Rouprêt, Per-Uno Malmstrom, Peter Black

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Presentation transcript:

European Urology Oncology Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer Jinhai Huo, Mohamed D. Ray-Zack, Yong Shan, Karim Chamie, Stephen A. Boorjian, Preston Kerr, Bagi Jana, Stephen J. Freedland, Ashish M. Kamat, Hemalkumar B. Mehta, Stephen B. Williams European Urology Oncology DOI: 10.1016/j.euo.2018.07.009 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 Derivation of the cohort size. SEER=Surveillance, Epidemiology and End Results. European Urology Oncology DOI: (10.1016/j.euo.2018.07.009) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 2 Neoadjuvant chemotherapy (NAC) use for (A) the overall cohort and (B) stratified by clinical stage. European Urology Oncology DOI: (10.1016/j.euo.2018.07.009) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 3 Neoadjuvant chemotherapy use and type of chemotherapy for patients with muscle-invasive bladder cancer stratified by chronic renal disease. There was no significant difference in neoadjuvant chemotherapy use between patients with and without chronic kidney disease (CKD). M-VAC=methotrexate, vinblastine, doxorubicin, and cisplatin; Gcisp=gemcitabine and cisplatin; Gcarb=gemcitabine and carboplatin. European Urology Oncology DOI: (10.1016/j.euo.2018.07.009) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 4 Kaplan-Meier curves for overall survival among patients with stage II muscle-invasive bladder cancer, stratified by use of neoadjuvant chemotherapy (NAC). European Urology Oncology DOI: (10.1016/j.euo.2018.07.009) Copyright © 2018 European Association of Urology Terms and Conditions